FABP4 and type 1 diabetes mellitus: Given that the present study identified FABP4 as an inflammatory regulator potentiating the TRM cell‐mediated adaptive immune activation before T1D onset, the proven similarity of immunology and pathology of human T1D and NOD mouse model,[38] and the metabolic benefits of FABP4 deletion,[60] the application of FABP4 neutralizing antibody as early intervention is a potential low‐risk immunotherapy option to delay T1D progression.